BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8523061)

  • 1. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
    Francis P; Rowinsky E; Schneider J; Hakes T; Hoskins W; Markman M
    J Clin Oncol; 1995 Dec; 13(12):2961-7. PubMed ID: 8523061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
    Armstrong DK; Fleming GF; Markman M; Bailey HH
    Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
    Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
    Markman M; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis JL; Rubin S; Curtin J; Barakat R; Phillips M
    J Clin Oncol; 1992 Sep; 10(9):1485-91. PubMed ID: 1355523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
    Markman M; Brady MF; Spirtos NM; Hanjani P; Rubin SC
    J Clin Oncol; 1998 Aug; 16(8):2620-4. PubMed ID: 9704711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N; Sill MW; Mannel RS; Thaker PH; DiSilvestro PA; Waggoner SE; Yamada SD; Armstrong DK; Fracasso PM; Walker JL
    Gynecol Oncol; 2012 Dec; 127(3):506-10. PubMed ID: 22943879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
    Cristea MC; Frankel P; Synold T; Rivkin S; Lim D; Chung V; Chao J; Wakabayashi M; Paz B; Han E; Lin P; Leong L; Hakim A; Carroll M; Prakash N; Dellinger T; Park M; Morgan RJ
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):589-598. PubMed ID: 30623229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions.
    Perng RP; Wu MF; Lin SY; Chen YM; Lin JY; Whang-Peng J
    Anticancer Drugs; 1997 Jul; 8(6):565-73. PubMed ID: 9300570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Backes FJ; Wei L; Chen M; Hill K; Dzwigalski K; Poi M; Phelps M; Salani R; Copeland LJ; Fowler JM; Cohn DE; Bixel K; Cosgrove C; Hays J; O'Malley D
    Gynecol Oncol; 2021 Sep; 162(3):619-625. PubMed ID: 34272090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
    Morgan MA; Darcy KM; Rose PG; DeGeest K; Bookman MA; Aikins JK; Sill MW; Mannel RS; Allievi C; Egorin MJ;
    Gynecol Oncol; 2008 Sep; 110(3):329-35. PubMed ID: 18597837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
    Dizon DS; Sill MW; Gould N; Rubin SC; Yamada SD; Debernardo RL; Mannel RS; Eisenhauer EL; Duska LR; Fracasso PM
    Gynecol Oncol; 2011 Nov; 123(2):182-6. PubMed ID: 21820161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
    ; Markman M; Blessing J; Rubin SC; Connor J; Hanjani P; Waggoner S
    Gynecol Oncol; 2006 Jun; 101(3):436-40. PubMed ID: 16325893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
    Taylor SE; Li R; Petschauer JS; Donovan H; O'Neal S; Keeler AW; Zamboni WC; Edwards RP; Zorn KK
    Gynecol Oncol; 2015 Sep; 138(3):548-53. PubMed ID: 26111788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
    Morgan MA; Sill MW; Fujiwara K; Greer B; Rubin SC; Degeest K; Yamada SD; Waggoner S; Coleman RL; Walker JL; Mannel RS
    Gynecol Oncol; 2011 May; 121(2):264-8. PubMed ID: 21277623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
    Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
    J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.